Eli Lilly and Company (LLY) P/E Ratio History
Historical price-to-earnings valuation from 1990 to 2026
Loading P/E history...
LLY Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 6, 2026, Eli Lilly and Company (LLY) trades at a price-to-earnings ratio of 43.1x, with a stock price of $988.19 and trailing twelve-month earnings per share of $28.21.
The current P/E is 32% below its 5-year average of 63.8x. Over the past five years, LLY's P/E has ranged from a low of 32.7x to a high of 116.1x, placing the current valuation at the 20th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.2x, LLY trades at a 94% premium to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 171.0x.
The PEG ratio of 1.49 (P/E divided by 96% EPS growth) suggests a fair valuation relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, LLY commands a significant premium over the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our LLY DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
LLY P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $151B | 12.4Lowest | 0.60Best | +2% | |
| $150B | 19.4 | - | -4% | |
| $279B | 15.5 | 0.73 | +8% | |
| $281B | 27.7 | 1.27 | +191%Best | |
| $116B | 16.5 | - | +178% | |
| $365B | 87.0 | - | -1% | |
| $544B | 39.0 | - | -58% | |
| $278B | 20.2 | 1.32 | +22% | |
| $178B | 23.2 | 7.87 | +88% | |
| $28B | 21.4 | - | -21% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
LLY Historical P/E Data (1990–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | $919.77 | $28.15 | 32.7x | +2% | |
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $1074.68 | $22.95 | 46.8x | +47% |
| FY2025 Q3 | $763.00 | $20.44 | 37.3x | +17% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $779.53 | $15.30 | 50.9x | +60% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $825.91 | $12.29 | 67.2x | +111% |
| FY2024 Q4 | $772.00 | $11.71 | 65.9x | +107% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $885.94 | $9.25 | 95.8x | +200% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $905.38 | $8.12 | 111.5x | +250% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $777.96 | $6.70 | 116.1x | +264% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $582.92 | $5.64 | 103.4x | +224% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $537.13 | $5.26 | 102.1x | +220% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $468.98 | $6.93 | 67.7x | +112% |
Average P/E for displayed period: 31.9x
Full LLY Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
Should I Buy LLY Right Now?
Bull case, key risks, Wall St analyst verdict, and what council investors are saying — updated daily.
See LLY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LLY Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LLY vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonLLY — Frequently Asked Questions
Quick answers to the most common questions about buying LLY stock.
Is LLY stock overvalued or undervalued?
LLY trades at 43.1x P/E, below its 5-year average of 63.8x. At the 20th percentile of historical range, the stock is priced at a discount to its own history.
How does LLY's valuation compare to peers?
Eli Lilly and Company P/E of 43.1x compares to sector median of 22.2x. The premium reflects expected growth above peers.
What is LLY's PEG ratio?
LLY PEG ratio is 1.49. Between 1-2 suggests valuation aligns with growth. Historical P/E data spans 1990-2026.